Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia

Journal of Clinical Pharmacology

Volumn 43, Issue 2, 2003, Pages 122-127

  Yasui Furukori, Norio ^a   Mihara, Kazuo ^b   Kondo, Tsuyoshi ^b   Kubota, Takahiro ^b   Iga, Tatsuji ^b   Takarada, Yutaka ^c   De Vries, Ronald ^d   Kaneko, Sunao ^a   Tateishi, Tomonori ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c TOYOBO CO LTD   (Japan)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; CYTOCHROME P450 2D6; FLUNITRAZEPAM; PALIPERIDONE; RISPERIDONE;

ADULT; ALLELE; ARTICLE; CATALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG HYDROXYLATION; DRUG METABOLISM; ENANTIOMER; ENANTIOSELECTIVITY; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JAPAN; LIVER METABOLISM; MALE; MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HALF-LIFE; HUMANS; HYDROXYLATION; ISOXAZOLES; JAPAN; MALE; PYRIMIDINES; RISPERIDONE; SCHIZOPHRENIA; STEREOISOMERISM;

EID: 12244295746     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270002239819     Document Type: Article

References (24)

1. 2 antagonistic properties. J Pharmacol Exp Ther 1988;244:685-693.
2. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA: Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1998;247:661-670.
3. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, et al: Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992;85:295-305.
4. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al: A Canadian multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
5. Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, et al: Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54:257-268.
6. Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J: Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993;21:1134-1141.
7. Scordo MG, Spina E, Facciola G, Avenoso A, Johansson I, Dahl ML: Cytochrome P450 2D6 genotype and steady state levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology 1999;147:300-305.
8. van Beijsterveldt LE, Geerts RJ, Leysen JE, Megens AA, Van den Eynde HM, Meuldermans WE, et al: Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology 1994;113:53-62.
9. Roh HK, Kim CE, Chung WG, Park CS, Svensson JO, Bertilsson L: Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 2002;57:671-675.
10. Heim M, Meyer UA: Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-532.
11. Steen VM, Andreassen OA, Daly AK, et al: Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995;5:215-223.
12. Johansson I, Oscarson M, Yue QY, et al: Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-459.
13. Kubota T, Yamaura Y, Ohkawa N, et al: Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6genotypes. Br J Clin Pharmacol 2000;50:31-34.
14. Chida M, Yokoi T, Nemoto N, et al: A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype. Pharmacogenetics 1999;9:287-293.
15. Yokoi T, Kosaka Y, Chida M, et al: A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogentics 1996;6:395-401.
16. Johansson I, Lundqvist E, Dahl ML, et al: PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 1996;6:351-355.
17. Tateishi T, Chida M, Ariyoshi N, et al: Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 1999;65:570-575.
18. Fukuda T, Nishida Y, Imaoka S, Hiroi T, Naohara M, Funae Y, et al: The decreased in vivo clearance of CYP2D6 substrates by CYP2D6* 10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch Biochem Biophys 2000;380:303-308.
19. Yasui-Furukori N, Hidestrand M, Spina E, Facciola G, Scordo MG, Tybring G: Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 2001;29:1263-1268.
20. American Psychiatric Association: Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
21. Ono S, Mihara K, Suzuki A, Kondo T, Yasui-Furukori N, Furukori H, et al: Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology 2002;162:50-54.
22. Snoeck E, Van Peer A, Sack M, Horton M, Mannens G, Woestenborghs R, et al: Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 1995;12:223-229.
23. Spina E, Avenoso A, Facciola G, Salemi M, Scordo MC, Ancione M, et al: Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmaco]ogy 2001;153:238-243.
24. Burke D, Henderson DJ: Chirality: a blueprint for the future. Br J Anaesth 2002;88:563-576.